Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > CD5


Brief Information

Name:T-cell surface glycoprotein CD5
Target Synonym:Epididymis Secretory Sperm Binding Protein,CD5,Lymphocyte antigen T1/Leu-1,T-cell surface glycoprotein CD5,CD5 Molecule,CD5 Antigen (P56-62),LEU1,CD5 Antigen,T1,CD5 Antigens
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:5
Lastest Research Phase:Phase 2 Clinical

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data

CD5-HP2H6-Cell-based assay
FACS assay shows that recombinant Biotinylated FACS

5e5 of anti-CD5 CAR-293 cells were stained with 100 μL of 1:25 dilution (4 μL stock solution in 100 μL FACS buffer) of PE-Labeled Human CD5, His Tag (Cat. No. CD5-HP2H6) and negative control protein respectively. PE signal was used to evaluate the binding activity (QC tested).


Immobilized Biotinylated Rhesus macaque CD5 Protein, His,Avitag (Cat. No. CD5-R82E3) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Anti-CD5 Antibody, Mouse IgG1 with a linear range of 0.1-1 ng/mL (QC tested).

CD5 MALS images

The purity of Rhesus macaque CD5 Protein, His Tag (Cat. No. CD5-R52H3) is more than 90% and the molecular weight of this protein is around 85-105 kDa verified by SEC-MALS.

Synonym Name



T-cell surface glycoprotein CD5 is also known as Lymphocyte antigen T1/Leu-1 and LEU1,which is phosphorylated on tyrosine residues by LYN,so CD5 can create binding sites for PTPN6/SHP-1.CD5 may act as a receptor in regulating T-cell proliferation. CD5 is expressed at various developmental and activation stages on human B cells.CD5 is a well established negative regulator of TCR and BCR signalling.CD5-positive cells may also prevent the emergence of autoimmunity by provision of cytokines such as IL-10. Development,selection and function of different B- and T-cell subsets or their preferential survival may be directly or indirectly dependent on different glycan structures associated with CD5 or CD5-like molecules.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
CD5 CAR-T Therapy(Xuanwu Hospital) Phase 1 Clinical Xuanwu Hospital Of Capital Medical University Precursor T-Cell Lymphoblastic Leukemia-Lymphoma Details
MT-101 MT-101 Phase 2 Clinical Myeloid Therapeutics Inc Lymphoma, T-Cell, Peripheral; Lymphoma, T-Cell, Cutaneous; Mycosis Fungoides Details
CD5 CAR T cell therapy (iCell Gene Therapeutics) Phase 1 Clinical Icell Gene Therapeutics (Int'L) Ltd Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell Details
CD5 CAR T (CT125B) therapy ( Beijing Boren Hospital) CD5 CAR T (CT125B); CT125B; CD5 CAR T Phase 1 Clinical Beijing Gao Boren Hospital Co Ltd Precursor T-Cell Lymphoblastic Leukemia-Lymphoma Details
CT-125A CT-125A; RD-125 Phase 1 Clinical Lymphoma, T-Cell, Peripheral; Hematologic Neoplasms; Lymphoma, Large B-Cell, Diffuse; Plasmablastic Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, T-Cell; Leukemia, Lymphocytic, Chronic, B-Cell Details

This web search service is supported by Google Inc.

Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
+1 888-377-6111
1 Innovation Way, Newark, DE 19711, USA

Leave a message